Status: Therapeutic Antibody Discovery

CGEN-15027 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen.

Studies by Compugen have shown that this immune checkpoint target is expressed in the cancer microenvironment, on cancer cells derived from lung, breast, and liver cancer patients.

Functional experiments where CGEN-15027 was overexpressed on CD8 cytotoxic T cells that recognize and destroy melanoma cancer cells, demonstrated lower cancer-specific reactivity of these T cells.

Currently, the research focus is on CGEN-15027 as ADC target